Inhibition of cancer progression by inhibiting PI3K/Akt/mTOR signaling pathway in various cancers such as prostate (Braglia et al., 2020), bladder (Li et al., 2022), breast (Song et al., 2022) and oral cancers (Marques et al., 2022). This evidence concerns the gene AKT1 and cancer.